Tempus AI, Inc. (NASDAQ:TEM) Director David R. Epstein Sells 620 Shares

Tempus AI, Inc. (NASDAQ:TEM) Director David R. Epstein sold 620 shares of the firm’s stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $41.81, for a total transaction of $25,922.20. Following the completion of the sale, the director now directly owns 27,894 shares in the company, valued at approximately $1,166,248.14. This trade represents a 2.17 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Tempus AI Stock Performance

Shares of TEM opened at $41.00 on Friday. The business has a 50-day simple moving average of $52.64. Tempus AI, Inc. has a fifty-two week low of $22.89 and a fifty-two week high of $79.49. The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. NEA Management Company LLC grew its position in Tempus AI by 17.8% during the 3rd quarter. NEA Management Company LLC now owns 5,385,979 shares of the company’s stock valued at $304,846,000 after purchasing an additional 813,169 shares during the last quarter. Novo Holdings A S bought a new position in shares of Tempus AI in the second quarter worth approximately $142,605,000. Revolution Growth Management Company Inc. purchased a new stake in shares of Tempus AI during the second quarter valued at approximately $128,133,000. ARK Investment Management LLC increased its position in shares of Tempus AI by 355.0% during the third quarter. ARK Investment Management LLC now owns 2,378,157 shares of the company’s stock valued at $134,604,000 after acquiring an additional 1,855,459 shares in the last quarter. Finally, Alphabet Inc. purchased a new position in Tempus AI in the 2nd quarter worth approximately $54,289,000. Institutional investors own 24.22% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. Guggenheim started coverage on Tempus AI in a research note on Monday, December 9th. They issued a “buy” rating and a $74.00 target price on the stock. Wolfe Research assumed coverage on shares of Tempus AI in a research report on Friday. They set an “outperform” rating and a $60.00 price objective on the stock. Stifel Nicolaus cut shares of Tempus AI from a “buy” rating to a “hold” rating and raised their target price for the stock from $45.00 to $65.00 in a research report on Monday, November 11th. Bank of America lifted their target price on shares of Tempus AI from $52.00 to $54.00 and gave the company a “neutral” rating in a research note on Friday. Finally, Piper Sandler reissued a “neutral” rating and issued a $70.00 price target (up from $40.00) on shares of Tempus AI in a research note on Tuesday, November 12th. Three investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $56.00.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.